LEPROSY, also known as HANSEN\'S DISEASE (HD), is a long-term infection by the bacterium Mycobacterium leprae or Mycobacterium lepromatosis . Initially, infections are without symptoms and typically remain this way for 5 to 20 years. Symptoms that develop include granulomas of the nerves , respiratory tract , skin, and eyes. This may result in a lack of ability to feel pain, thus loss of parts of extremities due to repeated injuries or infection due to unnoticed wounds. Weakness and poor eyesight may also be present.
* 1 Signs and symptoms
* 2 Cause
* 2.1 M. leprae * 2.2 Risk factors * 2.3 Transmission * 2.4 Genetics
* 3 Pathophysiology
* 4 Diagnosis
* 4.1 Classification
* 5 Prevention * 6 Treatment
* 7 Epidemiology
* 7.1 Disease burden
* 8 History
* 9 Society and culture
* 9.1 India * 9.2 Treatment cost * 9.3 Historical texts * 9.4 Middle Ages
* 9.5 19th century
* 9.5.1 Norway * 9.5.2 Colonialism and imperialism
* 9.6 Stigma * 9.7 Programs and treatment * 9.8 Notable cases
* 10 Other animals * 11 See also * 12 References * 13 External links
SIGNS AND SYMPTOMS
Hands deformed by leprosy *
A 26-year-old woman with leprous lesions *
A 13-year-old boy with severe leprosy
M. leprae, one of the causative agents of leprosy: As an acid-fast bacterium, M. leprae appears red when a Ziehl-Neelsen stain is used. Main article: Mycobacterium leprae
M. leprae and M. lepromatosis are the causative agents of leprosy. M. lepromatosis is a relatively newly identified mycobacterium isolated from a fatal case of diffuse lepromatous leprosy in 2008.
An intracellular, acid-fast bacterium , M. leprae is aerobic and
rod-shaped, and is surrounded by the waxy cell membrane coating
characteristic of the
Due to extensive loss of genes necessary for independent growth, M. leprae and M. lepromatosis are obligate intracellular pathogens , and unculturable in the laboratory, a factor that leads to difficulty in definitively identifying the organism under a strict interpretation of Koch\'s postulates . The use of nonculture-based techniques such as molecular genetics has allowed for alternative establishment of causation.
While the causative organisms have to date been impossible to culture in vitro, it has been possible to grow them in animals such as mice and armadillos.
Naturally occurring infection also has been reported in nonhuman primates, including the African chimpanzee , sooty mangabey , and cynomolgus macaque, as well as in armadillos and red squirrels .
Red squirrels (Sciurus vulgaris) - a threatened species - in England were found to have leprosy in November 2016. However, no squirrel cases have spread to a human for hundreds of years.
The greatest risk factor for developing leprosy is contact with
another case of leprosy. Contacts of people with leprosy are five to
eight times more likely to develop leprosy than members of the general
Other risk factors are poorly understood. However, conditions that
reduce immune function, such as malnutrition, other illnesses, or host
genetic differences, may increase the risk of developing leprosy.
Despite this, infection with
Transmission of leprosy occurs during close contact with those who are infected. Transmission is proposed to be by nasal droplets, but many questions remain about its mode of transmission and epidemiology.
Two exit routes of M. leprae from the human body often described are the skin and the nasal mucosa, although their relative importance is not clear. Lepromatous cases show large numbers of organisms deep in the dermis , but whether they reach the skin surface in sufficient numbers is doubtful.
The skin and the upper respiratory tract are most likely entry route. While older research dealt with the skin route, recent research has increasingly favored the respiratory route. Experimental transmission of leprosy through aerosols containing M. leprae in immunosuppressed mice was accomplished, suggesting a similar possibility in humans.
NAME LOCUS OMIM GENE
LPRS1 10p13 609888
LPRS4 6p21.3 610988 LTA
LPRS5 4p14 613223 TLR1
LPRS6 13q14.11 613407
Several genes have been associated with a susceptibility to leprosy.
Often, the immune system is able to eliminate leprosy during the early
infection stage before severe symptoms develop. A defect in
cell-mediated immunity may cause susceptibility to leprosy. The region
How the infection produces the symptoms of the disease is not known.
According to the World Health Organization, diagnosis in areas where people are frequently infected is based on one of these main signs:
* Skin lesion consistent with leprosy and with definite sensory loss * Positive skin smears
Skin lesions can be single or multiple, and usually hypopigmented, although occasionally reddish or copper-colored. The lesions may be macules (flat), papules (raised), or nodular. The sensory loss at the skin lesion is important because this feature can help differentiate it from other causes of skin lesions such as tinea versicolor . Thickened nerves are associated with leprosy and can be accompanied by loss of sensation or muscle weakness. However, without the characteristic skin lesion and sensory loss, muscle weakness is not considered a reliable sign of leprosy.
In some cases, acid-fast leprosy bacilli in skin smears are considered diagnostic; however, the diagnosis is clinical.
Diagnosis in areas where the disease is uncommon, such as the United States, is often delayed because healthcare providers are unaware of leprosy and its symptoms. Early diagnosis and treatment prevent nerve involvement, the hallmark of leprosy, and the disability it causes.
Many kinds of leprosy are known, but some symptoms are common to them, including runny nose, dry scalp, eye problems, skin lesions, muscle weakness, reddish skin, smooth, shiny, diffuse thickening of facial skin, ear, and hand, loss of sensation in fingers and toes, thickening of peripheral nerves, and flat nose due to destruction of nasal cartilage. Also, phonation and resonation of sound occur during speech. Often, atrophy of the testes with resulting impotence occurs.
Several different approaches for classifying leprosy exist, but parallels exist.
* The World Health Organization system distinguishes "paucibacillary" and "multibacillary" based upon the proliferation of bacteria. ("pauci-" refers to a low quantity.) * The SHAY scale provides five gradations. * The ICD-10 , though developed by the WHO, uses Ridley-Jopling and not the WHO system. It also adds an indeterminate ("I") entry. * In MeSH , three groupings are used.
WHO RIDLEY-JOPLING ICD-10 MESH DESCRIPTION LEPROMIN TEST
Paucibacillary tuberculoid ("TT"), borderline tuberculoid ("BT") A30.1, A30.2 Tuberculoid It is characterized by one or more hypopigmented skin macules and patches where skin sensations are lost because of damaged peripheral nerves that have been attacked by the human host's immune cells. Positive
Multibacillary midborderline or borderline ("BB") A30.3 Borderline Borderline leprosy is of intermediate severity and is the most common form. Skin lesions resemble tuberculoid leprosy, but are more numerous and irregular; large patches may affect a whole limb, and peripheral nerve involvement with weakness and loss of sensation is common. This type is unstable and may become more like lepromatous leprosy or may undergo a reversal reaction, becoming more like the tuberculoid form.
Multibacillary borderline lepromatous ("BL"), and lepromatous ("LL") A30.4, A30.5 Lepromatous It is associated with symmetric skin lesions , nodules , plaques , thickened dermis, and frequent involvement of the nasal mucosa resulting in nasal congestion and nose bleeds , but, typically, detectable nerve damage is late. Negative
A difference in immune response to the tuberculoid and lepromatous forms is seen.
* Early and indeterminate leprosy
Borderline tuberculoid leprosy
Borderline lepromatous leprosy
This disease may also occur with only neural involvement, without skin lesions.
Early detection of the disease is important, since physical and neurological damage may be irreversible even if cured. Medications can decrease the risk of those living with people with leprosy from acquiring the disease and likely those with whom people with leprosy come into contact outside the home. However, concerns are known of resistance, cost, and disclosure of a person's infection status when doing follow-up of contacts. Therefore, the WHO recommends that people who live in the same household be examined for leprosy and be treated only if symptoms are present.
The Bacillus Calmette–Guérin (BCG) vaccine offers a variable amount of protection against leprosy in addition to tuberculosis . It appears to be 26 to 41% effective (based on controlled trials) and about 60% effective based on observational studies with two doses possibly working better than one. Development of a more effective vaccine is ongoing.
MDT antileprosy drugs: standard regimens
A number of leprostatic agents are available for treatment. For paucibacillary (PB or tuberculoid) cases, treatment with daily dapsone and monthly rifampicin for six months is recommended. While for multibacillary (MB or lepromatous) cases, treatment with daily dapsone and clofazimine along with monthly rifampicin for 12 months is recommended.
Multidrug therapy (MDT) remains highly effective, and people are no
longer infectious after the first monthly dose. It is safe and easy
to use under field conditions due to its presentation in calendar
In 2015, the number of cases of leprosy was about 175,000 and the number of new cases was 210,000.
As of 2013, 14 countries contain 95% of the globally reported leprosy
cases. Of these, India has the greatest number of cases (59%),
The number of cases of leprosy was in the tens of millions in the
1960s; a series of national (the International Federation of
Although the number of new leprosy cases occurring each year is important as a measure of transmission, it is difficult to measure due to leprosy's long incubation period, delays in diagnosis after onset of the disease, and the lack of laboratory tools to detect it in the very early stages. Instead, the registered prevalence is used. Registered prevalence is a useful proxy indicator of the disease burden, as it reflects the number of active leprosy cases diagnosed with the disease and receiving treatment with MDT at a given point in time. The prevalence rate is defined as the number of cases registered for MDT treatment among the population in which the cases have occurred, again at a given point in time.
New case detection is another indicator of the disease that is usually reported by countries on an annual basis. It includes cases diagnosed with the onset of disease in the year in question (true incidence) and a large proportion of cases with onset in previous years (termed a backlog prevalence of undetected cases).
Endemic countries also report the number of new cases with established disabilities at the time of detection, as an indicator of the backlog prevalence. Determination of the time of onset of the disease is, in general, unreliable, is very labor-intensive, and is seldom done in recording these statistics.
Main article: History of leprosy G. H. A. Hansen , discoverer of M. leprae
Using comparative genomics, in 2005, geneticists traced the origins and worldwide distribution of leprosy from East Africa or the Near East along human migration routes. They found four strains of M. leprae with specific regional locations. Strain 1 occurs predominantly in Asia, the Pacific region, and East Africa; strain 4, in West Africa and the Caribbean; strain 3 in Europe, North Africa, and the Americas; and strain 2 only in Ethiopia, Malawi, Nepal/north India, and New Caledonia.
On the basis of this, they offer a map of the dissemination of leprosy in the world. This confirms the spread of the disease along the migration, colonisation, and slave trade routes taken from East Africa to India, West Africa to the New World, and from Africa into Europe and vice versa.
The oldest skeletal evidence for the disease was found in the human remains from the archaeological sites of Balathal and Harappa , in India and Pakistan, respectively.
Although retrospectively identifying descriptions of leprosy-like
symptoms is difficult, what appears to be leprosy was discussed by
Interpretations of the presence of leprosy have been made on the basis of descriptions in ancient Indian (Atharva Veda and Kausika Sutra), Greek, and Middle Eastern documentary sources that describe skin afflictions.
Skeletal remains from the second millennium BC, discovered in 2009,
represent the oldest documented evidence for leprosy. Located at
Balathal, in Rajasthan, northwest India, the discoverers suggest that
if the disease did migrate from Africa to India, during the third
millennium BC "at a time when there was substantial interaction among
the Indus Civilization, Mesopotamia, and Egypt, there needs to be
additional skeletal and molecular evidence of leprosy in India and
Africa so as to confirm the African origin of the disease." A proven
human case was verified by
The causative agent of leprosy, M. leprae, was discovered by G. H. Armauer Hansen in Norway in 1873, making it the first bacterium to be identified as causing disease in humans. The first effective treatment (promin ) became available in the 1940s. In the 1950s, dapsone was introduced. The search for further effective antileprosy drugs led to the use of clofazimine and rifampicin in the 1960s and 1970s. Later, Indian scientist Shantaram Yawalkar and his colleagues formulated a combined therapy using rifampicin and dapsone, intended to mitigate bacterial resistance. MDT combining all three drugs was first recommended by the WHO in 1981. These three antileprosy drugs are still used in the standard MDT regimens.
Resistance has developed to initial treatment. Until the introduction of MDT in the early 1980s, leprosy could not be diagnosed and treated successfully within the community.
Japan still has sanatoriums (although Japan's sanatoriums no longer have active leprosy cases, nor are survivors held in them by law).
The importance of the nasal mucosa in the transmission of M leprae was recognized as early as 1898 by Schäffer, in particular, that of the ulcerated mucosa.
SOCIETY AND CULTURE
Two lepers denied entrance to town, 14th century
India was one of the first countries to have acted against leprosy.
India enacted the
Between 1995 and 1999, the WHO, with the aid of the Nippon Foundation
, supplied all endemic countries with free MDT in blister packs,
channeled through ministries of health. This free provision was
extended in 2000 and again in 2005, 2010 and 2015 with donations by
the MDT manufacturer
Written accounts of leprosy date back thousands of years. Various skin diseases translated as leprosy appear in the ancient Indian text, the Atharava Veda , as early as 2000 BC. Another Indian text, the Laws of Manu (1500 BC), prohibited contact with those infected with the disease and made marriage to a person infected with leprosy punishable.
Biblically speaking, the Hebraic root tsara or tsaraath (צָרַע,
--tsaw-rah' -- to be struck with leprosy, to be leprous) and the Greek
(λεπρός - lepros), are of broader classification than the more
narrow use of the term related to Hansen's Disease. Any progressive
skin disease (a whitening or splotchy bleaching of skin, raised
manifestations of scales, scabs, infections, rashes, etc.…) as well
as generalized molds and surface discoloration of any clothing,
leather, and/or discoloration on walls surfaces throughout homes all
came under the "law of leprosy" (
The biblical perception that people with leprosy were unclean may be
connected to a passage from
Medieval leper bell
It is believed that a rise in leprosy in Europe occurred in the Middle Ages based on the increased number of hospitals created to treat leprosy patients in the 12th and 13th centuries. France alone had nearly 2,000 leprosariums during this period.
The social perception in medieval communities was generally one of fear, and those people infected with the disease were thought to be unclean, untrustworthy, and morally corrupt. People with leprosy were also often required to wear clothing that identified them as such or carry a bell announcing their presence. Segregation from mainstream society was common. The third Lateran Council of 1179 and a 1346 edict by King Edward expelled lepers from city limits. Because of the moral stigma of the disease, methods of treatment were both physical and spiritual, and leprosariums were established under the purview of the church.
Norway was the location of a progressive stance on leprosy tracking and treatment and played an influential role in European understanding of the disease. In 1832, Dr. JJ Hjort conducted the first leprosy survey, thus establishing a basis for epidemiological surveys. Subsequent surveys resulted in the establishment of a national leprosy registry to study the causes of leprosy and for tracking of the rate of infection.
Early leprosy research throughout Europe was conducted by Norwegian
Daniel Cornelius Danielssen and
Carl Wilhelm Boeck . Their
work resulted in the establishment of the National
Colonialism And Imperialism
Father Damien on his deathbed in 1889
Though leprosy in Europe was again on the decline by the 1860s, Western countries embraced isolation treatment out of fear of the spread of disease from developing countries, minimal understanding of bacteriology, lack of diagnostic ability or knowledge of how contagious the disease was, and missionary activity. Growing imperialism and pressures of the industrial revolution resulted in a Western presence in countries where leprosy was endemic, namely the British presence in India. Isolation treatment methods were observed by Surgeon-Mayor Henry Vandyke Carter of the British Colony in India while visiting Norway, and these methods were applied in India with the financial and logistical assistance of religious missionaries. Colonial and religious influence and associated stigma continued to be a major factor in the treatment and public perception of leprosy in endemic developing countries until the mid-twentieth century.
Despite effective treatment and education efforts, leprosy stigma continues to be problematic in endemic developing countries. Leprosy is most common amongst impoverished or marginalized populations where social stigma is likely to be compounded by other social inequities. Fears of ostracism, loss of employment, or expulsion from family and society may contribute to a delayed diagnosis and treatment.
Folk models of belief, lack of education, and religious connotations of the disease continue to influence social perceptions of those afflicted in many parts of the world. In Brazil, for example, folklore holds that leprosy is transmitted by dogs, it is a disease associated with sexual promiscuity, and is sometimes thought to be punishment for sins or moral transgressions. Socioeconomic factors also have a direct impact. Lower-class domestic workers who are often employed by those in a higher socioeconomic class may find their employment in jeopardy as physical manifestations of the disease become apparent. Skin discoloration and darker pigmentation resulting from the disease also have social repercussions.
In extreme cases in northern India, leprosy is equated with an "untouchable" status that "often persists long after (individuals with leprosy) have been cured of the disease, creating lifelong prospects of divorce, eviction, loss of employment, and ostracism from family and social networks."
PROGRAMS AND TREATMENT
The WHO states that diagnosis and treatment with MDT are easy and effective, and a 45% decline in disease burden has occurred since MDT has become more widely available. The organization emphasizes the importance of fully integrating leprosy treatment into public health services, effective diagnosis and treatment, and access to information.
In some instances in India, community-based rehabilitation is embraced by local governments and NGOs alike. Often, the identity cultivated by a community environment is preferable to reintegration, and models of self-management and collective agency independent of NGOs and government support have been desirable and successful.
* Saint Damien DeVeuster , a Roman Catholic priest from Belgium,
himself eventually contracting leprosy, ministered to lepers who had
been placed under a government-sanctioned medical quarantine on the
island of Molokaʻi in the Kingdom of Hawaiʻi .
Baldwin IV of Jerusalem was a Christian king of
Wild nine-banded armadillos (Dayspus novemcinctus) in south central United States often carry Mycobacterium leprae . This is believed to be because armadillos have such a low body temperature. Leprosy lesions appear mainly in cooler body regions such as the skin and mucous membranes of the upper respiratory tract . Because of armadillos' armor, skin lesions are hard to see. Abrasions around the eyes, nose and feet are the most common signs. Infected armadillos make up a large reservoir of M. leprae and may be a source of infection for some humans in the United States or other locations in the armadillos' home range. In armadillo leprosy, lesions did not persist at the site of entry in animals, M. leprae multiplied in macrophages at the site of inoculation and lymph nodes.
* ^ "Definition of leprosy". The Free Dictionary. Retrieved
* ^ A B C D E F G H I J K L M N O P Q R S Suzuki K, Akama T,
Kawashima A, Yoshihara A, Yotsu RR, Ishii N (February 2012). "Current
status of leprosy: epidemiology, basic science and clinical
perspectives.". The Journal of dermatology. 39 (2): 121–9. PMID
21973237 . doi :10.1111/j.1346-8138.2011.01370.x .
* ^ A B C D E F G H I J K L "
* ^ Brosch, Roland; Stinear, Timothy P. (11 November 2016).
* ICD -10 : A30 * ICD -9-CM : 030 * OMIM : 246300 * MESH : D007918 * DISEASESDB : 8478
* MEDLINEPLUS : 001347 * EMEDICINE : med/1281 derm/223 neuro/187 * PATIENT UK : Leprosy
Wikimedia Commons has media related to LEPROSY .
* v * t * e
Diseases of the skin and appendages by morphology
* seborrheic keratosis
* molluscum contagiosum
* actinic keratosis
* squamous-cell carcinoma
* basal-cell carcinoma
* Freckles * lentigo * melasma * nevus * melanoma
Dermal and subcutaneous
* epidermal inclusion cyst * hemangioma * dermatofibroma (benign fibrous histiocytoma) * keloid * lipoma * neurofibroma * xanthoma * Kaposi\'s sarcoma * infantile digital fibromatosis * granular cell tumor * leiomyoma * lymphangioma circumscriptum * myxoid cyst
With epidermal involvement
* contact dermatitis * atopic dermatitis * seborrheic dermatitis * stasis dermatitis * lichen simplex chronicus * Darier\'s disease * glucagonoma syndrome * langerhans cell histiocytosis * lichen sclerosus * pemphigus foliaceus * Wiskott–Aldrich syndrome * Zinc deficiency
* psoriasis * tinea (corporis * cruris * pedis * manuum * faciei ) * pityriasis rosea * secondary syphilis * mycosis fungoides * systemic lupus erythematosus * pityriasis rubra pilaris * parapsoriasis * ichthyosis
* herpes simplex * herpes zoster * varicella * bullous impetigo * acute contact dermatitis * pemphigus vulgaris * bullous pemphigoid * dermatitis herpetiformis * porphyria cutanea tarda * epidermolysis bullosa simplex
* scabies * insect bite reactions * lichen planus * miliaria * keratosis pilaris * lichen spinulosus * transient acantholytic dermatosis * lichen nitidus * pityriasis lichenoides et varioliformis acuta
* acne vulgaris * acne rosacea * folliculitis * impetigo * candidiasis * gonococcemia * dermatophyte * coccidioidomycosis * subcorneal pustular dermatosis
* tinea versicolor * vitiligo * pityriasis alba * postinflammatory hyperpigmentation * tuberous sclerosis * idiopathic guttate hypomelanosis * leprosy * hypopigmented mycosis fungoides
Without epidermal involvement
* drug eruptions * viral exanthems * toxic erythema * systemic lupus erythematosus
* cellulitis * abscess * boil * erythema nodosum * carcinoid syndrome * fixed drug eruption
* urticaria * erythema (multiforme * migrans * gyratum repens * annulare centrifugum * ab igne )
* thrombocytopenic purpura * actinic/solar purpura
* disseminated intravascular coagulation * vasculitis
* scleroderma /morphea * granuloma annulare * lichen sclerosis et atrophicus * necrobiosis lipoidica
* telogen effluvium * androgenic alopecia * alopecia areata * systemic lupus erythematosus * tinea capitis * loose anagen syndrome * lichen planopilaris * folliculitis decalvans * acne keloidalis nuchae
* onychomycosis * psoriasis * paronychia * ingrown nail
* Aphthous stomatitis * oral candidiasis * lichen planus * leukoplakia * pemphigus vulgaris * mucous membrane pemphigoid * cicatricial pemphigoid * herpesvirus * coxsackievirus * syphilis * systemic histoplasmosis * squamous-cell carcinoma
* v * t * e
* Whipple\'s disease
* Arcanobacterium haemolyticum infection
M. tuberculosis / M. bovis
* Meningitis * Rich focus
* M. kansasii
* M. marinum
* M. gordonae
* MAI infection
* M. ulcerans
* M. haemophilum
R4 /RG :
* M. fortuitum * M. chelonae * M. abscessus
* Corynebacterium diphtheriae
* Corynebacterium minutissimum
* Corynebacterium jeikeium
* GND : 4035392-8 * NDL : 00569249
Links: ------ /wiki/Chronic_(medicine) /wiki/Bacterium /wiki/Mycobacterium_leprae /wiki/Mycobacterium_lepromatosis